US$ 24.04
pots and semaglutide Do glucagon‑like peptide‑1 (GLP‑1) receptor agonists such as semaglutide, liraglutide, dulaglutide, tirzepatide improve symptoms of postural orthostatic tachycardia syndrome (POTS) and mast‑cell activation syndrome (MCAS)? Dr. Blitshteyn and her research
Description
FDA thresholds, insurance cutoffs, qualifying conditions, and more.
| Sarah Jones Simmer, CEO of Found, said that the trends are likely the result of irresponsible prescribing for recreational reasons causing the pendulum to swing "all the way in the other direction," and it's leading to patients who have genuine medical need struggling to access these therapies.

Implementation is designed to be fast and mistake proof
Always consult a qualified healthcare professional before starting, stopping, or changing any medication